Vaccination -

MMWR Booster for: Measles, Mumps, Rubella Vaccine (PRIORIX): Recommendations of the Advisory Committee on Immunization Practices — United States, 2022, Weekly / November 18, 2022 / 71(46);1465–1470

Posted on January 11, 2024 by Cody Micah Carmichael MPH, CPH

Top 5 Takeaways 1. PRIORIX, a new MMR (Measles, Mumps, and Rubella) vaccine, has been licensed and recommended by the Advisory Committee on Immunization Practices (ACIP) in the United States

MMWR Booster for: Safety Monitoring of JYNNEOS Vaccine During the 2022 Mpox Outbreak — United States, May 22–October 21, 2022 Weekly / December 9, 2022 / 71(49);1555–1559

Posted on January 7, 2024 by Cody Micah Carmichael MPH, CPH

Top 5 Takeaways: Nearly 1 million JYNNEOS doses administered: From May 22 to October 21, 2022, around 987,294 doses were given in the U.S., showing a safety profile consistent with

MMWR Booster for: Reduced Risk for Mpox After Receipt of 1 or 2 Doses of JYNNEOS Vaccine Compared with Risk Among Unvaccinated Persons — 43 U.S. Jurisdictions, July 31–October 1, 2022, Weekly / December 9, 2022 / 71(49);1560–1564

Posted on January 6, 2024 by Cody Micah Carmichael MPH, CPH

Top 5 Takeaways: Significantly Lower Incidence in Vaccinated Individuals: The study found that mpox incidence among unvaccinated individuals was 9.6 times higher than among those who received two doses of

Epidemiology, Broadly Speaking

Tag: Vaccination